Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease

Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Enriko Dolgov, David S. Perlin, Yanan Zhao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, has potent activity against a wide spectrum of fungal pathogens and is approved for the treatment of invasive aspergillosis, yet little is known about the tissue penetration of isavuconazole at the target sites of infection. Here, we explored the spatial and quantitative distribution of isavuconazole in tissue lesions in experimental pulmonary aspergillosis established in mice with chronic granulomatous disease (CGD) (gp91phox). Matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and laser capture microdissection (LCM)-directed high-pressure liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were used to analyze infected lungs and brain tissues collected 1, 3, 6, and 24 h after a single oral administration of the prodrug at a dose of 256 mg/kg of body weight (corresponding to 122.9 mg/kg of isavuconazole). Drug enrichment within granulomatous lesions was observed in lung tissue at 1 h postdose, although drug levels quickly equilibrated after-wards between lesion and nonlesion areas. A prominent antifungal effect in the infected lung tissue was revealed by histopathological analysis. Isavuconazole also penetrated into the brain with high efficiency. These data further support the value of isavuconazole to treat patients with invasive aspergillosis.

Original languageEnglish (US)
Article numbere00524-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Chronic Granulomatous Disease
Aspergillosis
Tissue Distribution
Infection
Prodrugs
Lung
Pulmonary Aspergillosis
Laser Capture Microdissection
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Brain
Tandem Mass Spectrometry
isavuconazole
Pharmaceutical Preparations
Oral Administration
High Pressure Liquid Chromatography
Body Weight

Keywords

  • Chronic granulomatous disease
  • Drug penetration
  • Invasive aspergillosis
  • Isavuconazole
  • Isavuconazonium sulfate
  • Laser capture microdissection
  • Matrix-assisted laser desorption ionization mass spectrometry imaging

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease. / Lee, Annie; Prideaux, Brendan; Lee, Min Hee; Zimmerman, Matthew; Dolgov, Enriko; Perlin, David S.; Zhao, Yanan.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 6, e00524-19, 01.06.2019.

Research output: Contribution to journalArticle

@article{661e801c3bbb41eb833247e6901ae192,
title = "Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease",
abstract = "Isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, has potent activity against a wide spectrum of fungal pathogens and is approved for the treatment of invasive aspergillosis, yet little is known about the tissue penetration of isavuconazole at the target sites of infection. Here, we explored the spatial and quantitative distribution of isavuconazole in tissue lesions in experimental pulmonary aspergillosis established in mice with chronic granulomatous disease (CGD) (gp91phox). Matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and laser capture microdissection (LCM)-directed high-pressure liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were used to analyze infected lungs and brain tissues collected 1, 3, 6, and 24 h after a single oral administration of the prodrug at a dose of 256 mg/kg of body weight (corresponding to 122.9 mg/kg of isavuconazole). Drug enrichment within granulomatous lesions was observed in lung tissue at 1 h postdose, although drug levels quickly equilibrated after-wards between lesion and nonlesion areas. A prominent antifungal effect in the infected lung tissue was revealed by histopathological analysis. Isavuconazole also penetrated into the brain with high efficiency. These data further support the value of isavuconazole to treat patients with invasive aspergillosis.",
keywords = "Chronic granulomatous disease, Drug penetration, Invasive aspergillosis, Isavuconazole, Isavuconazonium sulfate, Laser capture microdissection, Matrix-assisted laser desorption ionization mass spectrometry imaging",
author = "Annie Lee and Brendan Prideaux and Lee, {Min Hee} and Matthew Zimmerman and Enriko Dolgov and Perlin, {David S.} and Yanan Zhao",
year = "2019",
month = "6",
day = "1",
doi = "10.1128/AAC.00524-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease

AU - Lee, Annie

AU - Prideaux, Brendan

AU - Lee, Min Hee

AU - Zimmerman, Matthew

AU - Dolgov, Enriko

AU - Perlin, David S.

AU - Zhao, Yanan

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, has potent activity against a wide spectrum of fungal pathogens and is approved for the treatment of invasive aspergillosis, yet little is known about the tissue penetration of isavuconazole at the target sites of infection. Here, we explored the spatial and quantitative distribution of isavuconazole in tissue lesions in experimental pulmonary aspergillosis established in mice with chronic granulomatous disease (CGD) (gp91phox). Matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and laser capture microdissection (LCM)-directed high-pressure liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were used to analyze infected lungs and brain tissues collected 1, 3, 6, and 24 h after a single oral administration of the prodrug at a dose of 256 mg/kg of body weight (corresponding to 122.9 mg/kg of isavuconazole). Drug enrichment within granulomatous lesions was observed in lung tissue at 1 h postdose, although drug levels quickly equilibrated after-wards between lesion and nonlesion areas. A prominent antifungal effect in the infected lung tissue was revealed by histopathological analysis. Isavuconazole also penetrated into the brain with high efficiency. These data further support the value of isavuconazole to treat patients with invasive aspergillosis.

AB - Isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, has potent activity against a wide spectrum of fungal pathogens and is approved for the treatment of invasive aspergillosis, yet little is known about the tissue penetration of isavuconazole at the target sites of infection. Here, we explored the spatial and quantitative distribution of isavuconazole in tissue lesions in experimental pulmonary aspergillosis established in mice with chronic granulomatous disease (CGD) (gp91phox). Matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and laser capture microdissection (LCM)-directed high-pressure liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were used to analyze infected lungs and brain tissues collected 1, 3, 6, and 24 h after a single oral administration of the prodrug at a dose of 256 mg/kg of body weight (corresponding to 122.9 mg/kg of isavuconazole). Drug enrichment within granulomatous lesions was observed in lung tissue at 1 h postdose, although drug levels quickly equilibrated after-wards between lesion and nonlesion areas. A prominent antifungal effect in the infected lung tissue was revealed by histopathological analysis. Isavuconazole also penetrated into the brain with high efficiency. These data further support the value of isavuconazole to treat patients with invasive aspergillosis.

KW - Chronic granulomatous disease

KW - Drug penetration

KW - Invasive aspergillosis

KW - Isavuconazole

KW - Isavuconazonium sulfate

KW - Laser capture microdissection

KW - Matrix-assisted laser desorption ionization mass spectrometry imaging

UR - http://www.scopus.com/inward/record.url?scp=85066430393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066430393&partnerID=8YFLogxK

U2 - 10.1128/AAC.00524-19

DO - 10.1128/AAC.00524-19

M3 - Article

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

M1 - e00524-19

ER -